Korean patent received for VistaGen PH10 for treatment of major depressive disorder

VistaGen Therapeutics, a biopharmaceutical company, announced that the Korean property Office (KIPO) within the Republic of Korea has issued a choice to Grant application No. 10-2015-7020176 associated with methods of treating clinical depression with VistaGen’s PH10, an investigational neuroactive nasal spray designed to possess rapid-onset therapeutic potential in several neuropsychiatric indications involving depression, initially as potential stand-alone treatment for major clinical depression (MDD). The patent isn’t set to expire before 2034.

“The Republic of Korea is a crucial pharmaceutical market. With counterpart patents already issued within the US, Greater China, Europe and Japan, this patent enhances our patent protection for PH10 and may be a key component of our global commercial protection strategy for PH10,” stated Shawn K. Singh, chief military officer of VistaGen. “Our late-stage development and commercialization strategy for PH10 is analogous to our strategy for PH94B, namely, to license these rights in key pharmaceutical markets outside of North America.”

“MDD affects quite 264 million adults globally and may have significant emotional, functional and economic impact on those that suffer from the disorder and their loved ones. Recent studies have also shown that there has been an exacerbation of existing depression symptoms, with US adults showing 3 times as many symptoms of depression during the COVID-19 pandemic we are battling, making the necessity for better, safer alternatives for depression treatments more imperative. We believe PH10 has the potential to rework the treatment landscape for people with MDD in global depression markets, and that we believe this patent will help protect and propel global development,” continued Singh.

MDD may be a serious neurobiologically based mood disorder affecting quite 264 million adults globally and may be a leading explanation for disability worldwide. Individuals diagnosed with MDD exhibit depressive symptoms, like a depressed mood or a loss of interest or pleasure in daily activities, for quite a two-week period, also as impaired social, occupational, educational or other important functioning, which features a negative impact on their quality of life.

PH10 is an innovative odorless investigational synthetic neuroactive nasal spray designed to possess rapid-onset and therapeutic potential in several neuropsychiatric indications involving depression, including MDD and suicidal ideation. Following successfully completed exploratory phase 2A clinical development, VistaGen is preparing for phase 2B clinical development of PH10 as a possible stand-alone, rapid-onset treatment for MDD.

Also read:

Be the first to comment on "Korean patent received for VistaGen PH10 for treatment of major depressive disorder"

Leave a comment

Your email address will not be published.


*